Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

A process for manufacturing a mixture of straight-chain higher ethyleneamines and non-straight-chain higher ethyleneamines selected from branched higher ethyleneamines and cyclic higher ethyleneamines, or the urea derivatives thereof, includes reacting an amine-functional compound with an ethanolamine-functional compound in the presence of a carbon oxide delivering agent, wherein a) an amine-functional compound comprises a combination of straight-chain amine-functional compound and non-straight-chain amine-functional compound and is reacted with straight-chain ethanolamine-functional compound, or b) a straight-chain amine-functional compound is reacted with ethanolamine-functional compound comprising a combination of straight-chain ethanolamine-functional compound and non-straight-chain ethanolamine-functional compound, or c) an amine-functional compound comprising a combination of straight-chain amine-functional compound and non-straight-chain amine-functional compound is reacted with ethanolamine-functional compound comprising a combination of straight-chain ethanolamine-functional compound and non-straight-chain ethanolamine-functional compound.

A process for manufacturing a mixture of straight-chain higher ethyleneamines and non-straight-chain higher ethyleneamines selected from branched higher ethyleneamines and cyclic higher ethyleneamines, or the urea derivatives thereof, includes reacting an amine-functional compound with an ethanolamine-functional compound in the presence of a carbon oxide delivering agent, wherein a) an amine-functional compound comprises a combination of straight-chain amine-functional compound and non-straight-chain amine-functional compound and is reacted with straight-chain ethanolamine-functional compound, or b) a straight-chain amine-functional compound is reacted with ethanolamine-functional compound comprising a combination of straight-chain ethanolamine-functional compound and non-straight-chain ethanolamine-functional compound, or c) an amine-functional compound comprising a combination of straight-chain amine-functional compound and non-straight-chain amine-functional compound is reacted with ethanolamine-functional compound comprising a combination of straight-chain ethanolamine-functional compound and non-straight-chain ethanolamine-functional compound.

The present invention provides bumetanide analogs and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these bumetanide analogs and methods for their use. These analogs are believed useful for the treatment and/or prophylaxis of conditions that involve the Na.sup.+K.sup.+Cl.sup. co-transporter or GABA.sub.A receptor.

The present invention provides bumetanide analogs and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these bumetanide analogs and methods for their use. These analogs are believed useful for the treatment and/or prophylaxis of conditions that involve the Na.sup.+K.sup.+Cl.sup. co-transporter or GABA.sub.A receptor.

This application pertains to group 5 metal complexes having the structure of Formula I:

##STR00001##

and their potential utility in catalyzing -alkylation of secondary amine-containing moieties.

The present embodiment provides a compound represented by the formula (1):

Q-CHR.sub.2(1)

(Q is a nitrogen-containing aliphatic group containing two or more tertiary nitrogens but no oxygen, and R is an aliphatic group containing a biodegradable group). From the compound in combination with other lipids such as a lipid capable of reducing aggregation, lipid particles can be formed. Further, the compound can be used for a pharmaceutical composition to deliver an activator into cells.

The present embodiment provides a compound represented by the formula (1):

Q-CHR.sub.2(1)

(Q is a nitrogen-containing aliphatic group containing two or more tertiary nitrogens but no oxygen, and R is an aliphatic group containing a biodegradable group). From the compound in combination with other lipids such as a lipid capable of reducing aggregation, lipid particles can be formed. Further, the compound can be used for a pharmaceutical composition to deliver an activator into cells.

Methods and intermediates for synthesizing triethylenetetramine and salts thereof, as well as novel triethylenetetramine salts and their crystal structure, and triethylenetetramine salts of high purity.